ProBio Successfully Completes NMPA Pre-Approval Inspection for Biologics Manufacturing Facility in Nanjing, China
HOPEWELL, N.J., Oct. 21, 2026 /PRNewswire/ -- ProBio Inc., a global contract research, development and manufacturing organization (CRDMO), today announced the successful completion of a Pre-Approval Inspection (PAI) by China's National Medical Products Administration (NMPA) at its...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.